ArticleKorean journal of clinical oncology2026
Pathological tumor response and its association with recurrence patterns and survival after neoadjuvant chemoradiotherapy and esophagectomy for esophageal squamous cell carcinoma: a tertiary care center experience from India.
Article in Korean journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeoadjuvant chemoradiotherapy (NACRT) followed by esophagectomy is a standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Pathological response, assessed using tumor regression grade (TRG), is an established prognostic marker; however, evidence regarding its association with the pattern and timing of recurrence remains limited. This study evaluated recurrence patterns, timing of recurrence, and survival outcomes according to pathological tumor response following NACRT and esophagectomy for ESCC.
methodsWe retrospectively analyzed 129 patients with ESCC who underwent NACRT followed by radical esophagectomy between January 2013 and June 2023. Pathological response was assessed according to the College of American Pathologists TRG system and categorized as TRG 0 (complete response), TRG 1 (near-complete response), TRG 2 (partial response), or TRG 3 (poor/no response). Recurrence patterns and timing, disease-free survival, and overall survival were compared across TRG categories.
resultsAmong 129 patients, 33 (25.6%) developed recurrence. Systemic recurrence was the most common pattern (16/33, 48.5%), followed by combined locoregional and systemic recurrence (9/33, 27.3%) and isolated locoregional recurrence (8/33, 24.2%). Patients with TRG 0 had the lowest proportion of isolated locoregional recurrence (16.7%), with systemic and combined recurrence accounting for 50.0% and 33.3%, respectively. In contrast, TRG 3 patients predominantly developed isolated locoregional recurrence (80.0%), with systemic recurrence occurring in 20.0%; all recurrences in this group occurred within 12 months, suggesting poorer local disease control.
conclusionPoor pathological response was associated with earlier and predominantly locoregional recurrence, whereas favourable pathological response was associated with a greater proportion of systemic recurrence. These findings suggest that pathological tumor response may help inform postoperative risk stratification and guide individualized surveillance strategies in patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.